UCLH/UCL Biomedical Research Centre

ZS and IgniteData Partner to Transform Patient Data Automation for Clinical Trials

Retrieved on: 
Tuesday, February 1, 2022

The goal for this partnership is to improve the efficiency of clinical research through automation and use of real-world data, which will ultimately expedite pharmaceutical product and therapy innovation and improve patient outcomes.

Key Points: 
  • The goal for this partnership is to improve the efficiency of clinical research through automation and use of real-world data, which will ultimately expedite pharmaceutical product and therapy innovation and improve patient outcomes.
  • The partnership will enhance interoperability between electronic health records (EHR) and core research applications such as electronic data capture (EDC) systems to improve the efficiency of patient data collection for research institutions and sponsors within the context of clinical research.
  • ZSs vision is to transform what tomorrows research ecosystem looks like, stated Pratap Khedkar, CEO of ZS.
  • A key area of work is digital healthcare and enabling data-enabled trials in order to improve health through data.

Lifebit partners with NIHR Cambridge Biomedical Research Centre to launch the CYNAPSE platform for next-generation genomics research

Retrieved on: 
Tuesday, January 25, 2022

As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.

Key Points: 
  • As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.
  • The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research.
  • Based within the most outstanding NHS and University partnerships in the country, the Biomedical Research Centres are leaders in scientific translation.
  • Located on the Cambridge Biomedical Campus, they receive substantial levels of funding from the National Institute for Health Research (NIHR) to translate fundamental biomedical research into clinical research that benefits patients and they are early adopters of new treatments.

Lifebit partners with NIHR Cambridge Biomedical Research Centre to launch the CYNAPSE platform for next-generation genomics research

Retrieved on: 
Tuesday, January 25, 2022

As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.

Key Points: 
  • As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer.
  • The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research.
  • Based within the most outstanding NHS and University partnerships in the country, the Biomedical Research Centres are leaders in scientific translation.
  • Located on the Cambridge Biomedical Campus, they receive substantial levels of funding from the National Institute for Health Research (NIHR) to translate fundamental biomedical research into clinical research that benefits patients and they are early adopters of new treatments.

Abingworth portfolio company GammaDelta Therapeutics to be acquired by Takeda

Retrieved on: 
Wednesday, October 27, 2021

LONDON, Oct. 27, 2021 /PRNewswire/ -- Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited ("Takeda") for a pre-negotiated upfront payment, as well as potential development and regulatory milestones.

Key Points: 
  • LONDON, Oct. 27, 2021 /PRNewswire/ -- Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited ("Takeda") for a pre-negotiated upfront payment, as well as potential development and regulatory milestones.
  • Tim Haines, Abingworth Chair and Managing Partner, and Board Member at GammaDelta Therapeutics, commented: "It is extremely rewarding to see this successful outcome of a positive and productive collaboration between GammaDelta Therapeutics and Takeda.
  • GammaDelta Therapeutics ("GammaDelta") is clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer.
  • GammaDelta is advancing its novel, T cell platforms and product candidates under an ongoing collaboration with Takeda Pharmaceutical Company Limited ("Takeda").

Abingworth portfolio company GammaDelta Therapeutics to be acquired by Takeda

Retrieved on: 
Wednesday, October 27, 2021

LONDON, Oct. 27, 2021 /PRNewswire/ -- Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited ("Takeda") for a pre-negotiated upfront payment, as well as potential development and regulatory milestones.

Key Points: 
  • LONDON, Oct. 27, 2021 /PRNewswire/ -- Abingworth, a leading international life sciences investor, announces its portfolio company GammaDelta Therapeutics is to be acquired by Takeda Pharmaceutical Company Limited ("Takeda") for a pre-negotiated upfront payment, as well as potential development and regulatory milestones.
  • Tim Haines, Abingworth Chair and Managing Partner, and Board Member at GammaDelta Therapeutics, commented: "It is extremely rewarding to see this successful outcome of a positive and productive collaboration between GammaDelta Therapeutics and Takeda.
  • GammaDelta Therapeutics ("GammaDelta") is clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer.
  • GammaDelta is advancing its novel, T cell platforms and product candidates under an ongoing collaboration with Takeda Pharmaceutical Company Limited ("Takeda").

Genomics England Announces Appointment Of New Chief Scientific Officer

Retrieved on: 
Thursday, August 26, 2021

LONDON, Aug. 26, 2021 /PRNewswire/ -- GenomicsEngland today announces the appointment ofProfessor Matt Brownas the organisation's new Chief Scientific Officerfollowing arigorous recruitment process.

Key Points: 
  • LONDON, Aug. 26, 2021 /PRNewswire/ -- GenomicsEngland today announces the appointment ofProfessor Matt Brownas the organisation's new Chief Scientific Officerfollowing arigorous recruitment process.
  • He has a deep background in genomics, and has previously been Director of Genomics and Distinguished Professorat the Queensland University of Technology.
  • He established and directed one of Australia's largest cancer personalised medicine genomics services, the Australian Translational Genomics Centre, in Brisbane.
  • A spokesperson for Guy's and St Thomas'commented: "Congratulations to Professor Matt Brown on being appointed to the post of Chief Scientific Officer of Genomics England, an important national role drawing on his experience and research interests in genomics.

Global Academic Research Organization UCL Selects Phlexglobal's Innovative eTMF Solution to Enhance TMF Compliance and Inspection-Readiness Across Entire Study Portfolio

Retrieved on: 
Wednesday, July 28, 2021

PhlexTMF will support the entire portfolio at UCL's Institute of Clinical Trials and Methodology (ICTM), a pre-eminent center for clinical trials and amongst the largest of its kind in Europe.

Key Points: 
  • PhlexTMF will support the entire portfolio at UCL's Institute of Clinical Trials and Methodology (ICTM), a pre-eminent center for clinical trials and amongst the largest of its kind in Europe.
  • The decision by the UCL team followed a comprehensive tendering process with Phlexglobal appointed as the preferred bidder to help UCL streamline TMF management and oversight while reducing cost and risk.
  • "We're honored that a highly respected research organization like UCL selected Phlexglobal for their eTMF solution," said John McNeill, Chief Executive Officer of Phlexglobal.
  • The Institute of Clinical Trials and Methodology at UCL is a centre of excellence for clinical trials, meta analysis and epidemiological studies.